Safety and Efficacy of Cryoablation for Metastatic Lung Tumors

Inclusion Criteria: * Participant must be at least 18 years old. * Participant has signed a written informed consent. * Participant presents with Stage 4 pulmonary metastatic disease with metastatic disease previously confirmed by prior biopsy or confirmed on imaging with known primary disease. * Participant has up to 3 local metastases unilaterally targeted by cryoablation. Maximum of 5 total pulmonary tumors bilaterally. * Targeted tumor(s) defined as intra pulmonary or pleural with a maximum size of 3.5 cm. * The target tumor is determined (by CT/MRI) to be in a location where cryoablation is technically achievable based on the proximity of adjacent organs and structures. * Eastern Cooperative Oncology Group (ECOG) score of 0-2. * Karnofsky Performance Scale (KPS) score ≥60. * Platelet count \>50,000/cubed millimeters (mm\^3) within 60 days prior to study treatment. * International normalized ratio (INR) less than 1.5 within 60 days prior to study treatment. * Participant has a life expectancy of \>3 months. * Participant is clinically suitable for cryoablation procedure. Exclusion Criteria: * Participant's primary cancer is lung cancer. * Participant is unable to lie flat or has respiratory distress at rest. * Participant has uncontrolled coagulopathy or bleeding disorders. * Participant has had chemotherapy with neutropenia to levels as confirmed by absolute neutrophil count (ANC) of less than 1000 that produce increase risk for the cryoablation procedure. * Participant has a history of an allergic reaction to iodine injections or to shellfish. * Participant has evidence of active systemic, pulmonary, or pericardial infection. * Participant has a debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment or follow up. * Participant is currently participating in other experimental studies that could affect the primary endpoint.